Approval for fertility media in Australia

Approval for fertility media in Australia

As one of the first companies outside Australia, Vitrolife has received sales
approval from the Australian Medical Products Agency, TGA, for its fertility
media. This registration approval means that Vitrolife can now market its
products to all clinics on the same terms as local suppliers. TGA has after
review also issued a certificate regarding Vitrolife's quality system.

“The market in Australia is important as it is an opinion leader in large parts
of Asia and can form a bridgehead for continued expansion in the Asia/Pacific
region, which today has the fastest growth”, says Nils Sellbom, Vitrolife's
Sales Director. ”We also see that a great deal of pioneering research within IVF
and stem cells originates in clinics and universities in Australia.”

The Australian Medical Products Agency TGA has also issued a so-called
“Conformity Assessment Certificate” for Vitrolife's plant in Kungsbacka. The
certificate is based on an extensive examination of the business, and
recognition means that Vitrolife has a full quality management system applied
from the design until final inspection of the ready medical device.


October 30, 2007
Kungsbacka, Sweden 

Magnus Nilsson
CEO










Queries should be addressed to: 
Magnus Nilsson, CEO, phone +46 31 721 80 00 or +46 708 22 80 61.
Anna Ahlberg, CFO, phone +46 31 721 80 13 or +46 708 22 80 13.


________________________________________________________________________________
_________
Vitrolife is a global biotechnology/medical device Group that works with
developing, manufacturing and selling advanced products and systems for the
preparation, cultivation and storage of human cells, tissue and organs. The
company has business activities within three product areas: Fertility,
Transplantation and Stem Cell Cultivation. The Fertility product area works with
nutrient solutions (media) and advanced consumable instruments such as needles
and pipettes, for the treatment of human infertility. The Transplantation
product area works with solutions and systems to maintain tissue in optimal
condition outside the body for the required time while waiting for
transplantation. The Stem Cell Cultivation product area works with media and
instruments to enable the use and handling of stem cells for therapeutic
purposes. 
     Vitrolife today has approximately 140 employees and the company's products
are sold in more than 80 markets. The head office is in Kungsbacka, Sweden, and
there are subsidiaries outside Gothenburg, Sweden and in Denver, USA. The
Vitrolife share is listed on the OMX Nordic Exchange's Nordic Small Cap list.
________________________________________________________________________________
_________
Vitrolife AB (publ), Faktorvägen 13, SE-434 37 Kungsbacka, Sweden. Corporate
identity number 556354-3452.
Tel: +46 31 721 80 00. Fax: +46 31 721 80 90. E-mail: info@vitrolife.com.
Homepage: www.vitrolife.com.

This is a translation of the Swedish version of the press release. When in
doubt, the Swedish wording prevails.